Advertisement for orthosearch.org.uk
Results 1 - 2 of 2
Results per page:
Applied filters
Content I can access

Include Proceedings
Dates
Year From

Year To
Orthopaedic Proceedings
Vol. 92-B, Issue SUPP_IV | Pages 494 - 494
1 Oct 2010
Brecelj J Bole V
Full Access

Introduction: Substitution treatment and radiosynoviorthesis has a leading role in preventing irreversible hemophilic arthropaties. Aim: The aim of the study is to evaluate the effects of radiosynovectomy on the length of intervals between subsequent bleedings in patients with hemophilic synovitis. Materials and Methods: 33 joints were treated with radiosynovectomy in 28 patients with bleeding disorders. 90Y colloid was used in knees and 186Re colloid for elbow, shoulder and ankle. 20 patients were on prophylaxis. X-rays of treated joints were evaluated on Peterson scale between 0 (normal) and 13 (severe joint destruction). In observation period (range 6 – 44 months) bleeding episodes were recorded and data statistically analyzed. Results: Before RS, the average interval between haemorrhages was 16.4 days. Immediately after RS, the average interval between haemorrhages more than tripled. Namely, the average length of the first non-bleeding interval after RS was almost 60 days. In the period covering the first five bleeding episodes after RS, the average non-bleeding interval increased to 47.1 days. Therapeutic effects of RS considerably depend on location (joint) of bleeding, damage of the joint and of the patient. But controlling for location and damage of the joint and age of the patient, after RS every sub sequent non-bleeding interval was 11% shorter (p=0.05) than previous non-bleeding interval. After more than 10 bleeding episodes had occurred since RS, the non-bleeding intervals were no longer significantly shorter than before RS (at p=0.05). Therapeutic response to RS could be, therefore, observed in the period of more than 430 days after the procedure. Conclusion: Radiosynovectomy significantly reduces hemorrhages in target joints for the average period of 14 months. It is more efficient in patients with less affected joints and less efficient in younger patients. The therapeutic effect of RS diminished with the elapse of time


The Bone & Joint Journal
Vol. 98-B, Issue 10_Supple_B | Pages 34 - 40
1 Oct 2016
Emerson RH Alnachoukati O Barrington J Ennin K

Aims

Approved by the Food and Drug Administration in 2004, the Phase III Oxford Medial Partial Knee is used to treat anteromedial osteoarthritis (AMOA) in patients with an intact anterior cruciate ligament. This unicompartmental knee arthroplasty (UKA) is relatively new in the United States, and therefore long-term American results are lacking.

Patients and Methods

This is a single surgeon, retrospective study based on prospectively collected data, analysing a consecutive series of primary UKAs using the Phase III mobile-bearing Oxford Knee and Phase III instrumentation.

Between July 2004 and December 2006, the senior author (RHE) carried out a medial UKA in 173 patients (213 knees) for anteromedial osteoarthritis or avascular necrosis (AVN).

A total of 95 patients were men and 78 were women. Their mean age at surgery was 67 years (38 to 89) and mean body mass index 29.87 kg/m2 (17 to 62).

The mean follow-up was ten years (4 to 11).